

Loading Dose Series Protocol

- Nebulize 3mL Alpha2EQ[®] combined with 3mL saline/LRS
- Series of 6 dose spaced at 48 hour intervals
- It is recommended to hand walk the horse while nebulizing

Research

An open-label, single arm study was done to assess safety and clinical effects on 34 horses diagnosed with mild asthma based on clinical signs and/or BALs across 6 U.S. sites using the following qualifications:

- Pre-Rx weighted clinical score (WCS) was taken at Day 0 based on 9 respiratory related clinical signs, modified from Tesarowski 1996
- Day 0 WCS > 7 to qualify for the study
- No changes in management or medications allowed

Horses were treated with Alpha2EQ in a series of 6 doses at 48 hour intervals.

Post-Rx WCS was taken 7 days after completion of the final dose.

- Considered a success if reduction in WCS > 30% at post treatment evaluation AND final WCS score < 7

Totals:

- **30/34 (88.2%) met objective outcome success**
- **34/34 (100%) Post-Rx WCS < Pre-Rx WCS**
- **32/34 (94.1%) improved > 30%**

Safety:

- No adverse events reported. No significant changes in TPR. No epistaxis. One horse experienced transient increased coughing during one nebulization.

Duration of response:

- Varies between 1 month to ongoing (> 6 months)
- Some horses (higher initial WCS) remain on a single dose monthly

Anecdotal BAL results post-protocol have shown decreased neutrophils, eosinophils, and mast cells.

Using a bronchodilator prior to Alpha2EQ[®] has shown to be helpful with severe mucus cases.